News and Announcements
OpenDNA Launches New Artificial Intelligence App Featuring Their Own Technology
- Published July 12, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OpenDNA Limited (ASX:OPN) has recently released news of new AI-powered app featuring the company’s personalisation technology. The new app, called “Robb reader”, uses thr power of OpenDNA’s AI and machine learning technology to deliver curated content which is personalised to the specific interests of each individual reader.
KEY TAKEAWAYS:
- OpenDNA-powered “Robb Reader” app launched.
- The app delivers curated content to match the interests of each reader as they browse the magazine online, including the ability for readers to regulate and alter to their own interests within the settings of the app.
- The Robb Report Australia app is available through Apple Store and Google Play.
Jay Shah, CEO of OpenDNA, says: “Robb Report is not only a household name but a prestigious, well-respected and high-value brand. We are pleased to showcase how our artificial intelligence-driven personalisation technology can enhance the mobile experience for its readership. Through use of OpenDNA technology, content is quickly tailored to each Robb Report reader to create a much richer, more relevant and personalised experience.”
Elizabeth Walker, Brand and Communications Director at Robb Report Australia, said: “OpenDNA understands the discerning tastes of our audience and we recognised how OpenDNA technology could enhance the user experience. Our readers have come to expect an extremely high level of quality from our magazine content and OpenDNA tailors that experience to the individual reader.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
